4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Laekna, Inc. (2105) operates in the Biotechnology industry and is headquartered in Yuyao, China with about 83 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 2105 reported CNY 107M in revenue and (CNY 229M) in net income.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 107M | CNY 0M | CNY 0M | CNY 0M | — |
| Gross Profit | CNY 86M | CNY 0M | — | — | — |
| Operating Income (EBIT) | (CNY 264M) | (CNY 289M) | (CNY 306M) | (CNY 393M) | — |
| Net Income | (CNY 229M) | (CNY 254M) | (CNY 369M) | (CNY 782M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 1.4B | CNY 960M | CNY 932M | CNY 480M | — |
| Total Liabilities | CNY 234M | CNY 155M | CNY 128M | CNY 2.4B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2105 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms